Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast

Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Profitability

This table compares Context Therapeutics and Clearmind Medicine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-47.04%	-44.08%
Clearmind Medicine	N/A	-207.53%	-100.70%

Earnings and Valuation

This table compares Context Therapeutics and Clearmind Medicine”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$26.73 million	($0.38)	-7.03
Clearmind Medicine	N/A	N/A	-$3.86 million	($19.72)	-0.04

Context Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Context Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500.

Institutional and Insider Ownership

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 2.8% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Context Therapeutics and Clearmind Medicine, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1	0	7	1	2.89
Clearmind Medicine	0	0	0	0	0.00

Context Therapeutics presently has a consensus target price of $6.60, indicating a potential upside of 147.19%. Given Context Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Context Therapeutics is more favorable than Clearmind Medicine.

Summary

Context Therapeutics beats Clearmind Medicine on 9 of the 12 factors compared between the two stocks.

About Context Therapeutics

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

About Clearmind Medicine

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.